Effects of Synbiotics and Probiotics Supplementation on Serum Levels of Endotoxin, Heat Shock Protein 70 Antibodies and Inflammatory Markers in Hemodialysis Patients: a Randomized Double-Blinded Controlled Trial
The aim of this study was to investigate the effects of probiotic and synbiotic supplementation on serum inflammatory markers, endotoxin, and anti-HSP70 in hemodialysis (HD) patients. This study was a randomized, double-blind, placebo-controlled trial. Seventy-five hemodialysis patients who met the inclusion and exclusion criteria were randomly assigned for 12 weeks to one of the three arms: synbiotics [n = 23; 15 g of prebiotics, 5 g of probiotic powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-6, and Bifidobacterium longum LAF-5 (2.7 × 107 CFU/g each)], probiotics [n = 23; 5 g probiotics as in synbiotic group with 15 g of maltodextrin in the sachet as placebo], and placebo [n = 19; 20 g of maltodextrin in the sachet]. Blood and feces were collected at baseline and after intervention. Serum high sensitive C-reactive protein (hs-CRP), interleukin-6, endotoxin, and anti-heat shock protein 70 antibodies (anti-HSP70) were measured. The number of fecal colonies was determined using the plate-counting method. The mean serum level of hs-CRP, anti-HSP70, and endotoxin decreased significantly between groups (p = 0.007, p = 0.037, and p = 0.036, respectively). For the synbiotic group, the mean changes in hs-CRP and IL-6 were significantly lower than for the placebo (p < 0.001 and p < 0.001, respectively) and probiotic group (p = 0.011 and p = 0.008, respectively). Anti-HSP70 mean changes in the synbiotic and probiotic groups differed from the placebo group (p = 0.002 and p = 0.013, respectively). Administration of synbiotics was more effective than probiotics for improvement of inflammatory markers, endotoxin and anti-HSP70 serum levels. Trial registration number: IRCT2017041233393N1
KeywordsSynbiotics Probiotics Hemodialysis Inflammation Anti-HSP70
Compliance with Ethical Standards
The study was conducted according to the guidelines of the Helsinki Declaration and all procedures involving human patients were approved by the Ethics Committee of Ahvaz University of Medical Sciences (university ethics code: IR.AJUMF.REC.1395.812). Written informed consent was obtained from all patients before initiating the study.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 11.Haghighat N, Mohammadshahi M, Shayanpour S, Haghighizadeh MH (2018) Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics Antimicrob Proteins. https://doi.org/10.1007/s12602-018-9477-9
- 16.Sabico S, Al-Mashharawi A, Al-Daghri NM, Wani K, Amer OE et al (2018) Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.08.009
- 17.Sabico S, Al-Mashharawi A, Al-Daghri NM, Yakout S, Alnaami AM et al (2017) Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial. J Transl Med 15:249CrossRefGoogle Scholar
- 18.McFarlane C, Ramos CI, Johnson DW, Campbell KL (2018) Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr. https://doi.org/10.1053/j.jrn.2018.08.008
- 26.Zilaee M, Kermany T, Tavalaee S, Salehi M, Ghayour-Mobarhan M, Ferns GAA (2014) Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity C-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial. Phytother Res 28:1211–1215CrossRefGoogle Scholar
- 27.Moohebati M, Bidmeshgi S, Azarpazhooh MR, Daloee MH, Ghayour-Mobarhan M, Tavallaie S, Amini M, Momenzadeh A, Sahebkar A, Paydar R, Rahsepar AA, Parizadeh SMR, Akhlaghi S, Ferns GAA (2011) Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: a randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem 44:192–197CrossRefGoogle Scholar